Experiments were performed in order to ascertain the action of D-penicillamine (PA) on adjuvant arthritis (AA) in rats and to develop a quantitative evaluation method for PA-like drugs, using Lewis, SD, and Wistar rats. Rats were inoculated in the tail with 0.6 mg of Mycobacterium butyricum suspended in 0.1 ml of liquid paraffin. PA apparently induced enhancement of arthritis only in Lewis rats with a good reproducibility. The enhancing effect of PA was seen when it was administered during the period from day -7 to day -1, from day 0 to day 6, or from day 14 to day 20. In control group of Lewis and Wistar rats, adjuvant caused a rapid increase in the cell number of lymph nodes just after the inoculation, and also a marked increase in spleen cells coinciding with the development of arthritis. In PA-treated Lewis rats, the cell numbers of lymph nodes and spleen significantly surpassed those of control rats. However, PA induced no difference from control in Wistar rats, which were not sensitive to PA treatment during the course of arthritis. These results indicate that AA in Lewis rats is a good model for evaluating the activities of PA-like drugs and that PA may affect lymphocytes in lymph nodes and spleen and induce severer arthritis in Lewis rats.

Animals↗

PubMed1985

[Current problems in the surgical treatment of acquired heart disease].

Two hundred and ninety patients with ischemic heart disease and two hundred and sixty one patients with valvular heart disease have been operated upon in our department. Combined valvular and coronary artery surgery was carried out in 19 cases, coronary artery and peripheral vascular surgery was carried out in 7 cases, and tricuspid valve replacement with SJM was carried out in 20 cases. Early mortality rate of combined valvular and coronary artery surgery was 26%, and late mortality 21%, however, only 3 cases (15.8%) died of LOS. Mortality rate of combined coronary artery and peripheral vascular surgery was 43%, however 1 patient died of LOS. Mortality rate of TVR with SJM was 15% which was rather low in comparison with other valves. A patient who underwent simultaneous surgical treatment of valvular or peripheral vascular disease, and coronary artery disease, ran almost the same risk of LOS as patients without ischemic heart disease. However, myocardial protection was important for these patients because of severe LV dysfunction and myocardial hypertrophy. There is not yet an ideal artificial valve for TVR. At present, SJM is the best available valve in terms of design and hemodynamics.

Adult↗

PubMed1984